会计年度:2021-12-31收入分布
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| 合计 | 1,645,816,399.14 | 746,693,821.04 | 899,122,578.10 | 54.63 |
| 其他(补充) | 11,298,408.05 | 8,459,133.14 | 2,839,274.91 | 25.13 |
| 医药流通 | 798,305,444.68 | 508,302,013.58 | 290,003,431.10 | 36.33 |
| 医药制造 | 836,212,546.41 | 229,932,674.32 | 606,279,872.09 | 72.50 |
|
会计年度:2020-12-31
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| 合计 | 1,386,038,580.46 | 639,831,869.96 | 746,206,710.50 | 53.84 |
| 其他 | 12,712,914.81 | 10,245,802.39 | 2,467,112.42 | 19.41 |
| 其他(补充) | 18,436,571.08 | 14,761,007.99 | 3,675,563.09 | 19.94 |
| 医药流通 | 535,573,132.62 | 459,747,795.31 | 75,825,337.31 | 14.16 |
| 医药制造 | 819,315,961.95 | 155,077,264.27 | 664,238,697.68 | 81.07 |
|
会计年度:2019-12-31
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| 合计 | 1,290,332,662.74 | 513,694,948.93 | 776,637,713.81 | 60.19 |
| 抗过敏类 | 234,971,916.27 | 54,101,241.40 | 180,870,674.87 | 76.98 |
| 泌尿系统类 | 135,464,577.60 | 28,681,832.38 | 106,782,745.22 | 78.83 |
| 皮质激素类 | 29,670,389.38 | 19,870,631.26 | 9,799,758.12 | 33.03 |
| 片剂 | 709,752,104.07 | 242,314,428.84 | 467,437,675.23 | 65.86 |
| 其他 | 182,388,642.00 | 153,082,721.93 | 29,305,920.07 | 16.07 |
| 其他(补充) | 2,864,467.91 | 2,119,955.18 | 744,512.73 | 25.99 |
| 其他类 | 777,497,440.98 | 392,457,194.46 | 385,040,246.52 | 49.52 |
| 心血管类 | 109,863,870.60 | 16,464,094.25 | 93,399,776.35 | 85.01 |
| 原料药 | 172,304,201.06 | 94,355,000.92 | 77,949,200.14 | 45.24 |
| 针剂 | 223,023,247.70 | 21,822,842.06 | 201,200,405.64 | 90.22 |
|
会计年度:2018-12-31
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| 合计 | 1,019,238,732.07 | 320,073,933.16 | 699,164,798.91 | 68.60 |
| 抗过敏类 | 160,870,317.30 | 54,195,685.76 | 106,674,631.54 | 66.31 |
| 泌尿系统类 | 104,274,696.63 | 29,787,324.63 | 74,487,372.00 | 71.43 |
| 皮质激素类 | 67,824,020.74 | 45,677,547.19 | 22,146,473.55 | 32.65 |
| 片剂 | 508,952,419.56 | 144,628,149.33 | 364,324,270.23 | 71.58 |
| 其他 | 45,097,887.20 | 26,158,913.65 | 18,938,973.55 | 42.00 |
| 其他(补充) | 843,221.07 | 615,890.80 | 227,330.27 | 26.96 |
| 其他类 | 545,245,821.57 | 158,070,038.50 | 387,175,783.07 | 71.01 |
| 心血管类 | 140,180,654.76 | 31,727,446.28 | 108,453,208.48 | 77.37 |
| 原料药 | 149,639,868.85 | 81,623,341.30 | 68,016,527.55 | 45.45 |
| 针剂 | 314,705,335.39 | 67,047,638.08 | 247,657,697.31 | 78.70 |
|
会计年度:2017-12-31
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| 合计 | 685,401,776.96 | 210,687,050.08 | 474,714,726.88 | 69.26 |
| 片剂 | 419,720,753.41 | 112,016,414.57 | 307,704,338.84 | 73.31 |
| 其他 | 11,464,620.70 | 9,173,918.22 | 2,290,702.48 | 19.98 |
| 原料药 | 108,670,826.83 | 62,159,712.95 | 46,511,113.88 | 42.80 |
| 针剂 | 145,545,576.02 | 27,337,004.34 | 118,208,571.68 | 81.22 |
|
1/8 转到 
